| 23667/34351 | US=65 / Biol/Mol Cox JH, Overall CM. Cytokine substrates: MMP regulation of inflammatory signaling molecules. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 519-39. ISBN 978-0-387-69056-8. SUBSTRATOS DE CITOCINAS; MMP; REGULACAO DE MOLECULAS; SINALIZACAO INFLAMATORIAS; INFLAMACAO; QUIMIOCINAS |
| 23668/34351 | US=65 / Biol/Mol Lynch CC, Matrisian LM. Matrix metalloproteinases as key regulators of tumor-bone interraction. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 541-66. ISBN 978-0-387-69056-8. |
| 23669/34351 | US=65 / Biol/Mol Christensen IJ, Pappot H, Hoyer-Hansen G. The plasminogen activation system as a source of prognostic markers in cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 569-86. ISBN 978-0-387-69056-8. SISTEMA DE ATIVACAO DO PLASMINOGENIO; MARCADORES; PROGNOSTICO NO CANCER; UPA; UPAR; PAI-1; CANCER DE MAMA; CANCER COLORRETAL; CANCER DE PULMAO; CANCER GINECOLOGICO; CANCER DE PROSTATA |
| 23670/34351 | US=65 / Biol/Mol Lah TT, Obermajer N, Alonso MBD, Kos J. Cysteine cathepsins and cystatins as cancer biomarkers. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 587-625. ISBN 978-0-387-69056-8. CATEPSINAS; CISTEINA; CISTATINAS; BIOMARCADORES DE CANCER; PEPTIDASES; PESQUISA CLINICA; CARCINOMA DE MAMA; CARCINOMA DE PROSTATA; CARCINOMA DO COLO DO UTERO; CARCINOMA DE OVARIO; CARCINOMA DE PULMAO; CARCINOMA DE COLON; CARCINOMA DE CABECA E PESCOCO; CARCINOMA DA BEXIGA; CARCINOMA DE PANCREAS; CANCER DE FIGADO; CARCINOMA HEPATOCELULAR; MELANOMA; MENINGIOMA; GLIOMA |
| 23671/34351 | US=65 / Biol/Mol Pennington CJ, Pilgrim S, Span PN, Sweep FC, Edwards DR. Novel degradome markers in breast cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 627-43. ISBN 978-0-387-69056-8. CANCER DE MAMA; MARCADORES DEGRADOME; ASSINATURAS DE EXPRESSAO; PERFIL DE EXPRESSAO DEGRADOME; METALOPROTEINASE POTENCIAL; MARCADORES INIBIDORES |
| 23672/34351 | US=65 / Biol/Mol Iljin K, Kilpinen S, Ivaska J, Kallioniemi O. Meta-analysis of gene expression microarray data: degradome genes in healthy and cancer tissues. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 645-61. ISBN 978-0-387-69056-8. CANCER; GENES DEGRADOME; META-ANALISE DE DADOS; EXPRESSAO GENICA DE MICROARRAY |
| 23673/34351 | US=65 / Biol/Mol Laxton R, Ye S. Degradome gene polymorphisms. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 663-77. ISBN 978-0-387-69056-8. GENE DEGRADOME; POLIMORFISMOS; MMP1; MMP2; MMP3; MMP9; MMP12 |
| 23674/34351 | US=65 / Biol/Mol Frederiksen C, Lomholt AF, Nielsen HJ, Brünner N. TIMP-1 as a prognostic marker in colorectal cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 679-96. ISBN 978-0-387-69056-8. |
| 23675/34351 | US=65 / Biol/Mol Jacobsen B, Kjaergaard M, Gardsvoll H, Ploug M. Structure and inhibition of the urokinase-type plasminogen activator receptor. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 699-719. ISBN 978-0-387-69056-8. ATIVADOR DO PLASMINOGENIO TIPO UROQUINASE; UPAR; ANTICORPOS MONOCLONAIS; ANTAGONISTAS PEPTIDICOS |
| 23676/34351 | US=65 / Biol/Mol Stoppelli MP, Andersen LM, Votta G, Andreasen PA. Engineered antagonists of uPA and PAI-1. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 721-58. ISBN 978-0-387-69056-8. UPA; PAI-1; ATIVACAO DO PLASMINOGENIO; DISSEMINACAO DO CANCER; PROPRIEDADES BIOQUIMICAS; ADESAO CELULAR; MIGRACAO CELULAR; INVASAO CELULAR; PROLIFERACAO CELULAR; SOBREVIVENCIA; APOPTOSE; ATIVIDADE ENZIMATICA |
| 23677/34351 | US=65 / Biol/Mol Fingleton B. MMP inhibitor clinical trials-the past, present, and future. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 759-85. ISBN 978-0-387-69056-8. |
| 23678/34351 | US=65 / Biol/Mol Nagase H, Murphy G. Tailoring TIMPs for selective metalloproteinase inhibition. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 787-810. ISBN 978-0-387-69056-8. TIMPS; INIBICAO SELETIVA DE METALOPROTEINASE; PROPRIEDADES BIOQUIMICAS |
| 23679/34351 | US=65 / Biol/Mol Yiotakis A, Dive V. Third-Generation MMP inhibitors: recent advances in the development of highly selective inhibitors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 811-25. ISBN 978-0-387-69056-8. INIBIDORES DE MMP; GRUPOS DE LIGACAO DE ZINCO; FOSFINICOS; TRANSICAO ANALOGOS |
| 23680/34351 | US=65 / Biol/Mol Fields GB. Protease-activated delivery and imaging systems. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 827-51. ISBN 978-0-387-69056-8. PROTEASE; SISTEMAS DE IMAGEM; PRO-DROGAS; SISTEMA DE ENTREGA |
| 23681/34351 | US=65 / Biol/Mol Gill JH, Loadman PM. Development of tumour-selective and endoprotease-activated anticancer therapeutics. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 853-76. ISBN 978-0-387-69056-8. DESENVOLVIMENTO DE TUMORES SELETIVOS; ENDOPROTEASE ATIVADO; TERAPEUTICA ANTICANCER |
| 23682/34351 | US=65 / Biol/Mol Ala-aho R, Baker AH, Kähäri VM. Targeting degradome genes via engineered viral vectors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 877-94. ISBN 978-0-387-69056-8. SEGMENTACAO GENES DEGRADOME; VETORES VIRAIS; VETORES RETROVIRAIS; VETORES DE ADENOVIRUS; VETORES DE VIRUS ADENO-ASSOCIADOS; BACULOVIRUS; HERPES SIMPLEX |
| 23683/34351 | US=67 / Biol/Mol Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2 |
| 23684/34351 | US=67 / Biol/Mol Easton JB, Houghton PJ. mTOR: properties and therapeutics. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 33-53. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MTOR; PROPRIEDADES; TERAPEUTICA; INIBIDORES; RAPAMICINA; CANCER; ENSAIOS CLINICOS |
| 23685/34351 | US=67 / Biol/Mol Sparano JA. Ras/Raf/MEK inhibitors. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 55-73. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 23686/34351 | US=67 / Biol/Mol Neckers L, Ivy P. 17-AAG: targeting the molecular chaperone heat shock protein 90. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 75-95. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. 17-AAG; CHAPERONE; PROTEINA DE CHOQUE TERMICO 90; CANCER; CHAPERONE MOLECULAR; TERAPIA ALVO; PLASTICIDADE GENETICA; ONCOGENE; GELDANAMICINA; ANSAMICINA BENZOQUINONA |